A Blueprint for High Affinity SARS-CoV‑2 Mpro Inhibitors from Activity-Based Compound Library Screening Guided by Analysis of Protein Dynamics.

MLA

Gossen, Jonas, et al. “A Blueprint for High Affinity SARS-CoV‑2 Mpro Inhibitors from Activity-Based Compound Library Screening Guided by Analysis of Protein Dynamics.” ACS Pharmacology & Translational Science, vol. 4, no. 3, June 2021, pp. 1079–95. EBSCOhost, https://doi.org/10.1021/acsptsci.0c00215.

APA

Gossen, J., Albani, S., Hanke, A., Joseph, B. P., Bergh, C., Kuzikov, M., Costanzi, E., Manelfi, C., Storici, P., Gribbon, P., Beccari, A. R., Talarico, C., Spyrakis, F., Lindahl, E., Zaliani, A., Carloni, P., Wade, R. C., Musiani, F., Kokh, D. B., & Rossetti, G. (2021). A Blueprint for High Affinity SARS-CoV‑2 Mpro Inhibitors from Activity-Based Compound Library Screening Guided by Analysis of Protein Dynamics. ACS Pharmacology & Translational Science, 4(3), 1079–1095. https://doi.org/10.1021/acsptsci.0c00215

Chicago

Gossen, Jonas, Simone Albani, Anton Hanke, Benjamin P. Joseph, Cathrine Bergh, Maria Kuzikov, Elisa Costanzi, et al. 2021. “A Blueprint for High Affinity SARS-CoV‑2 Mpro Inhibitors from Activity-Based Compound Library Screening Guided by Analysis of Protein Dynamics.” ACS Pharmacology & Translational Science 4 (3): 1079–95. doi:10.1021/acsptsci.0c00215.